undamentalytics Newsletter
Sign in

Celldex Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Celldex Therapeutics, Inc. had total assets of $583m, total liabilities of $55.8m and shareholders' equity of $527m. It held $28.9m in cash against $0 of debt: net cash of $28.9m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents5721122516928724240241144392935282947
Receivables—00000122312003120
Total current assets—6355853052052951961459967198411318432747535725
Goodwill—9999999191—————————
Total assets—11098126347248338383316156123236445353466792583782
Accounts payable—111232221111333115
Total current liabilities—2014182024303528131214171931405161
Total debt09911—0000000000000
Total liabilities—35293027364711879322926252736455668
Shareholders' equity7475699632021229026523612494209419326429747527715
Net debt (negative = net cash)−57−12−3−14−169−28−72−42−40−24−11−44−39−29−35−28−29−47
Shares outstanding————————18m———47m47m56m66m67m79m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CLDX vs CLNNCLDX vs IBIOCLDX vs LSTAAIM vs CLDX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Celldex Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Celldex Therapeutics, Inc.